|

EU-Ocrevus Clinical Trials

1 actively recruiting trial

Also known as: Ocrelizumab

Pipeline

Phase 3: 1

Top Sponsors

  • Celltrion1

Indications

  • Relapsing Remitting Multiple Sclerosis1
  • Multiple Sclerosis1

Other1 trial

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.